期刊文献+

Clinical randomized comparative trial of DICE regimen and CHOP regimen in treating intermediate and high grade non-Hodgkin’s lymphoma

DICE方案与CHOP方案治疗中高度恶性非霍奇金淋巴瘤的随机对照研究(英文)
下载PDF
导出
摘要 Objective: To compare efficacies and safeties of DICE and CHOP regimens in treating intermediate and high grade non-Hodgkin's lymphoma (NHL), and indicate the standard treatment for it. Methods: A total of 74 patients with moder- ately or highly malignant NHL, verified by pathology or histology, were randomized into the trial group (37 patients treated with DICE regimen) and the control group (37 patients treated with CHOP regimen). Survival rate was analyzed by Kaplan-Meier method. Chi-square test was performed between groups. Results: The complete response rate, partial response rate, and response rate were significantly higher in DICE group than in CHOP group (40.5% vs. 29.7%, 37.8% vs. 27.0%, and 78.3% vs. 56.7%, respectively, P < 0.05). The 1-, 3-, and 5-year survival rates were significantly higher in DICE group than in CHOP group (89.2% vs. 81.2%, 76.0% vs. 52.6%%, and 46.7% vs. 36.4%, respectively, P < 0.05). The major side effects, appeared with no differences (P > 0.05) in incidences between the two groups, were leukopenia, thrombocytopenia, and nausea. There were only three episodes of clinical cystitis or gross haematuria in DICE regimen. Conclusion: The results showed higher efficacy of DICE regimen over CHOP regimen. DICE regimen may prolong the survival time of patients with moderately and highly malignant NHL.
机构地区 Department of Oncology
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第2期107-110,共4页 中德临床肿瘤学杂志(英文版)
关键词 non-Hodgkin's lymphoma combined chemotherapy comparative trial DICE方案 CHOP方案 治疗方案 中高度恶性非霍奇金淋巴瘤 随机对照
  • 相关文献

参考文献7

  • 1Messori A, Vaiani M, Trippoli S, et al. Survial in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Cancer, 2001,84: 303-307.
  • 2Haim N, Rosenblatt E, Wollner M, et al. Salvage therapy for nonHodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and cisplatin. Cancer Chemother Pharmacol, 1992, 30: 243-244.
  • 3Multani P, White CA, Grillo-Lopez A. Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol, 2001, 2: 279-291.
  • 4Gisselbrecht C, Mounier N. Improing second-line therapy in aggressive non-Hodgkin's lymphoma. Semin Oncol, 2004, 31: 12-16.
  • 5Kimby E, Brandt L, Nygren P, et al. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol, 2001,40: 198-212.
  • 6Loehrer PJ Sr, Laurer R, Roth B J, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med, 1998, 109: 540-546.
  • 7Coleman M, Leonard J, Shuster MW, et al. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Eur J Haematol Suppl, 2001.64: 41-45.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部